Sean P Cleary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4921185/publications.pdf

Version: 2024-02-01

151	8,603	42	88
papers	citations	h-index	g-index
155	155	155	13189
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1579-1591.	1.5	29
2	Long-term outcomes of laparoscopic liver resection for hepatocellular carcinoma: A propensity score matched analysis of a high-volume North American center. Surgery, 2022, 171, 982-991.	1.9	5
3	ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1594-1595.	1.5	O
4	PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Gaâ€PSMAâ€11 PET Using Cyclotronâ€Produced 68Ga. Hepatology Communications, 2022, 6, 1172-1185.	4.3	15
5	Surgical practice patterns and outcomes in T2 and T3 gallbladder cancer: a population-based study. Canadian Journal of Surgery, 2022, 65, E16-E24.	1.2	1
6	Contemporary outcomes of pancreaticoduodenectomy for benign and precancerous cystic lesions. Hpb, 2022, 24, 1416-1424.	0.3	7
7	Hepatocellular carcinoma as predominant cancer subgroup accounting for sex differences in post-hepatectomy liver failure, morbidity and mortality. Hpb, 2022, 24, 1453-1463.	0.3	2
8	Tranexamic acid versus placebo to reduce perioperative blood transfusion in patients undergoing liver resection: protocol for the haemorrhage during liver resection tranexamic acid (HeLiX) randomised controlled trial. BMJ Open, 2022, 12, e058850.	1.9	1
9	Radiation Segmentectomy for the Treatment of Solitary Hepatocellular Carcinoma: Outcomes Compared with Those of Surgical Resection. Journal of Vascular and Interventional Radiology, 2022, 33, 775-785.e2.	0.5	9
10	"Answers in hours― A prospective clinical study using nanopore sequencing for bile duct cultures. Surgery, 2022, 171, 693-702.	1.9	12
11	Dynamic risk profiling of HCC recurrence after curative intent liver resection. Hepatology, 2022, 76, 1291-1301.	7.3	21
12	Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasms. Hpb, 2022, 24, 1186-1193.	0.3	3
13	Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection. Hpb, 2022, , .	0.3	2
14	Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. Hpb, 2022, 24, 1957-1966.	0.3	4
15	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology, 2021, 73, 14-26.	7.3	66
16	Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery. Hepatology, 2021, 73, 1956-1966.	7.3	13
17	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 341-349.	4.2	268
18	Significance of proximal ductal margin status after resection of hilar cholangiocarcinoma. Hpb, 2021, 23, 109-117.	0.3	6

#	Article	IF	CITATIONS
19	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. Journal of Gastrointestinal Oncology, 2021, 12, 2275-2286.	1.4	4
20	Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Frontiers in Oncology, 2021, 11, 651119.	2.8	7
21	Finding the Balance: General Surgery Resident Versus Fellow Training and Exposure in Hepatobiliary and Pancreatic Surgery. Journal of Surgical Education, 2021, 78, 875-884.	2.5	3
22	Perception versus reality: A National Cohort Analysis of the surgeryâ€first approach for resectable pancreatic cancer. Cancer Medicine, 2021, 10, 5925-5935.	2.8	3
23	Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 2021, 124, 1077-1084.	1.7	3
24	Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspiration. Surgery, 2021, 170, 1794-1798.	1.9	2
25	Synchronous resection of colorectal cancer primary and liver metastases: an outcomes analysis. Hpb, 2021, 23, 1277-1284.	0.3	20
26	Synchronous colorectal liver metastases: therapeutic considerations. Hepatobiliary Surgery and Nutrition, 2021, 10, 711-713.	1.5	4
27	International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic Practice. Annals of Surgery, 2021, 274, 50-56.	4.2	9
28	Preoperative opioid use is associated with increased length of stay after pancreaticoduodenectomy. Hpb, 2020, 22, 1074-1081.	0.3	4
29	Acute and early EUS-guided transmural drainage of symptomatic postoperative fluid collections. Gastrointestinal Endoscopy, 2020, 91, 1085-1091.e1.	1.0	17
30	Emergent pancreatectomy for neoplastic disease: outcomes analysis of 534 ACS-NSQIP patients. BMC Surgery, 2020, 20, 169.	1.3	8
31	Distinct classes of multi-subunit heterogeneity: analysis using Fourier Transform methods and native mass spectrometry. Analyst, The, 2020, 145, 4688-4697.	3.5	10
32	En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent. Journal of the American College of Surgeons, 2020, 231, 8-29.	0.5	42
33	AHPBA Webinar about Covid-19: lessons learned responding to a pandemic. Hpb, 2020, 22, 1135-1138.	0.3	0
34	Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. JHEP Reports, 2020, 2, 100068.	4.9	18
35	Trajectories of physical activity, from young adulthood to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada. BMC Cancer, 2020, 20, 139.	2.6	5
36	Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. European Journal of Surgical Oncology, 2020, 46, 789-795.	1.0	15

#	Article	IF	CITATIONS
37	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery, 2020, 167, 803-811.	1.9	32
38	Effect of vessel preservation on splenic volume and function in patients with spleen preserving distal pancreatectomies. Hpb, 2020, 22, 1563-1568.	0.3	7
39	A Novel Clinically Based Staging System for Gallbladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 151-159.	4.9	13
40	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 554-561.	1.4	31
41	Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery, 2019, 166, 547-555.	1.9	72
42	Minimally Invasive Management of Secondary Liver Cancer. Surgical Oncology Clinics of North America, 2019, 28, 229-241.	1.5	8
43	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell, 2019, 35, 267-282.e7.	16.8	151
44	Renal outcomes following left renal vein harvest for venous reconstruction during pancreas and liver surgery. Hpb, 2019, 21, 114-120.	0.3	7
45	Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1700-1705.	1.0	9
46	Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case–control study in Ontario, Canada. Cancer Causes and Control, 2019, 30, 955-966.	1.8	16
47	Epsteinâ€Barr virusâ€nssociated smooth muscle tumors after lung transplantation. Transplant Infectious Disease, 2019, 21, e13068.	1.7	9
48	Cost Effectiveness of Hepatocellular Carcinoma SurveillanceÂAfter a Sustained Virologic Response to TherapyÂin Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1840-1849.e16.	4.4	82
49	Effect of portal vein embolization on treatment plan prior to major hepatectomy for hepatocellular carcinoma. Hpb, 2019, 21, 1072-1078.	0.3	5
50	Management and surveillance of non-functional pancreatic neuroendocrine tumours: Retrospective review. Pancreatology, 2019, 19, 360-366.	1.1	7
51	A Canadian strategy for surgical quality improvement. Canadian Journal of Surgery, 2019, 62, E16-E18.	1.2	3
52	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	6.3	21
53	Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas. Hpb, 2019, 21, 643-652.	0.3	22
54	Patient blood management for liver resection: consensus statements using Delphi methodology. Hpb, 2019, 21, 393-404.	0.3	7

#	Article	IF	CITATIONS
55	Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3†cm in potentially transplantable patients. Journal of Hepatology, 2019, 70, 866-873.	3.7	96
56	Liberating Native Mass Spectrometry from Dependence on Volatile Salt Buffers by Use of $G\tilde{A}_i$ bor Transform. ChemPhysChem, 2019, 20, 519-523.	2.1	17
57	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. Hpb, 2019, 21, 379-386.	0.3	11
58	Inâ€hospital opioid consumption, but not pain intensity scores, predicts 6â€month levels of pain catastrophizing following hepatic resection: A trajectory analysis. European Journal of Pain, 2019, 23, 503-514.	2.8	11
59	Laparoscopic colectomy: trends in implementation in Canada and globally. Canadian Journal of Surgery, 2019, 62, 139-141.	1.2	8
60	AB007. S2-1. Liver-directed therapy for cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, AB007-AB007.	1.5	0
61	Considering the cost of a simultaneous versus staged approach to resection of colorectal cancer with synchronous liver metastases in a publicly funded healthcare model. Journal of Surgical Oncology, 2018, 117, 1376-1385.	1.7	13
62	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
63	Implementation of prospective, surgeon-driven, risk-based pathway for pancreatoduodenectomy results in improved clinical outcomes and first year cost savings of \$1 million. Surgery, 2018, 163, 495-502.	1.9	15
64	Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. Annals of Surgical Oncology, 2018, 25, 991-999.	1.5	25
65	Medial Open Transversus Abdominis Plane (MOTAP) Catheters Reduce Opioid Requirements and Improve Pain Control Following Open Liver Resection. Annals of Surgery, 2018, 268, 233-240.	4.2	19
66	Minimally Invasive Liver Surgery: Has it Achieved the Standard of Care?. Annals of Surgical Oncology, 2018, 25, 1105-1107.	1.5	7
67	Two <i>BRM</i> promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. Molecular Carcinogenesis, 2018, 57, 106-113.	2.7	10
68	Exome-Wide Association Study of Pancreatic Cancer Risk. Gastroenterology, 2018, 154, 719-722.e3.	1.3	38
69	How Do Different Indices of Hepatic Enhancement With Gadoxetic Acid Compare in Predicting Liver Failure and Other Major Complications After Hepatectomy?. Journal of Computer Assisted Tomography, 2018, 42, 380-386.	0.9	4
70	Synchronous colorectal liver metastases: a national survey of surgeon opinions on simultaneous resection and multidisciplinary cooperation. Hepatobiliary Surgery and Nutrition, 2018, 7, 242-250.	1.5	12
71	Large Hepatic Mass in an Adolescent Male. Gastroenterology, 2018, 155, e9-e10.	1.3	1
72	Assessing tools for management of noncolorectal nonneuroendocrine liver metastases: External validation of a prognostic model. Journal of Surgical Oncology, 2018, 118, 1006-1011.	1.7	3

#	Article	lF	Citations
73	Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection. Journal of the American College of Surgeons, 2018, 227, 255-269.	0.5	91
74	A Review of Circulating Tumor DNA in Hepatobiliary Malignancies. Frontiers in Oncology, 2018, 8, 212.	2.8	10
75	Extracting Charge and Mass Information from Highly Congested Mass Spectra Using Fourier-Domain Harmonics. Journal of the American Society for Mass Spectrometry, 2018, 29, 2067-2080.	2.8	23
76	The effect of a simultaneous versus a staged resection of metastatic colorectal cancer on time to adjuvant chemotherapy. Journal of Surgical Oncology, 2018, 118, 86-94.	1.7	7
77	Primary perivascular epithelioid cell tumors of the liver: CT/MRI findings and clinical outcomes. Abdominal Radiology, 2017, 42, 1705-1712.	2.1	27
78	Trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer: A systematic review. Surgery, 2017, 161, 618-627.	1.9	65
79	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2017, 3, 774.	7.1	221
80	The economics of recovery after pancreatic surgery: detailed cost minimization analysis of an enhanced recovery program. Hpb, 2017, 19, 1026-1033.	0.3	24
81	Effect of Pancreatic Fistula on Recurrence and Long-Term Prognosis of Periampullary Adenocarcinomas after Pancreaticoduodenectomy. American Surgeon, 2016, 82, 1187-1195.	0.8	10
82	The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology, 2016, 64, 2077-2088.	7. 3	256
83	Fourier Analysis Method for Analyzing Highly Congested Mass Spectra of Ion Populations with Repeated Subunits. Analytical Chemistry, 2016, 88, 6205-6213.	6.5	29
84	Survival Following Resection of Intra- and Extra-Hepatic Metastases from Colorectal Cancer: A Phase II Trial. Annals of Surgical Oncology, 2016, 23, 2644-2651.	1.5	15
85	A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature, 2016, 538, 378-382.	27.8	418
86	<i>BRM</i> polymorphisms, pancreatic cancer risk and survival. International Journal of Cancer, 2016, 139, 2474-2481.	5.1	15
87	Comparison of Clinical Outcomes following Glue versus Polyvinyl Alcohol Portal Vein Embolization for Hypertrophy of the Future Liver Remnant prior to Right Hepatectomy. Journal of Vascular and Interventional Radiology, 2016, 27, 1897-1905.e1.	0.5	40
88	The comparative costs of laparoscopic and open liver resection: a report for the 2nd International Consensus Conference on Laparoscopic Liver Resection. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4691-4696.	2.4	26
89	Risk of extracolonic cancers for people with biallelic and monoallelic mutations in <i>MUTYH</i> International Journal of Cancer, 2016, 139, 1557-1563.	5.1	107
90	Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Letters, 2016, 370, 302-312.	7.2	47

#	Article	IF	Citations
91	Canadian Association of General Surgeons position statement: recommendations for surgeons with blood-borne communicable diseases. Canadian Journal of Surgery, 2016, 59, 83-86.	1.2	1
92	Comparison of expectations between medical oncologists (MO) and hepatobiliary surgeons (HS) regarding the indications for liver metastatectomy Journal of Clinical Oncology, 2016, 34, e18129-e18129.	1.6	0
93	What is the best technique in parenchymal transection in laparoscopic liver resection? Comprehensive review for the clinical question on the 2nd International Consensus Conference on Laparoscopic Liver Resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 363-370.	2.6	55
94	<scp><i>TERT</i></scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	5.1	57
95	The Toronto General Hospital Transitional Pain Service: development and implementation of a multidisciplinary program to prevent chronic postsurgical pain. Journal of Pain Research, 2015, 8, 695.	2.0	214
96	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1229-1238.	2.5	44
97	The effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustration. Genomics, 2015, 106, 340-347.	2.9	6
98	Management of umbilical hernias in patients with ascites: development of a nomogram to predict mortality. American Journal of Surgery, 2015, 209, 302-307.	1.8	21
99	Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene. Familial Cancer, 2015, 14, 575-583.	1.9	11
100	Common variation at $2p13.3$, $3q29$, $7p13$ and $17q25.1$ associated with susceptibility to pancreatic cancer. Nature Genetics, 2015 , 47 , $911-916$.	21.4	224
101	Hepato-pancreato-biliary surgery workforce in Canada. Canadian Journal of Surgery, 2015, 58, 212-215.	1.2	6
102	Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. Journal of Clinical Oncology, 2015, 33, 1835-1844.	1.6	54
103	Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods. Annals of Surgical Oncology, 2015, 22, 1160-1167.	1.5	55
104	Canadian practice patterns for pancreaticoduodenectomy. Canadian Journal of Surgery, 2015, 58, 121-127.	1.2	8
105	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids. Nature Medicine, 2015, 21, 1364-1371.	30.7	591
106	Laparoscopic versus open liver resection for hepatocellular carcinoma at a North-American Centre: a 2-to-1 matched pair analysis. Hpb, 2015, 17, 304-310.	0.3	43
107	Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Annals of Surgery, 2015, 261, 619-29.	4.2	891
108	Association between Alcohol Consumption and Pancreatic Cancer Risk: A Case-Control Study. PLoS ONE, 2015, 10, e0124489.	2.5	33

#	Article	IF	CITATIONS
109	Aberrant right hepatic artery in pancreaticoduodenectomy for adenocarcinoma: impact on resectability and postoperative outcomes. Hpb, 2014, 16, 204-211.	0.3	31
110	Risk of Colorectal Cancer for Carriers of Mutations in MUTYH, WithÂand Without a Family History of Cancer. Gastroenterology, 2014, 146, 1208-1211.e5.	1.3	180
111	Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. Hpb, 2014, 16, 475-480.	0.3	27
112	Combined pancreaticoduodenectomy and colon resection for locally advanced peri-ampullary tumours: analysis of peri-operative morbidity and mortality. Hpb, 2014, 16, 797-800.	0.3	13
113	Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center. Annals of Surgical Oncology, 2014, 21, 2708-2716.	1.5	16
114	Consensus and controversy in hepatic surgery: A survey of Canadian surgeons. Journal of Surgical Oncology, 2014, 110, 947-951.	1.7	23
115	Risk factors associated with recurrence in patients with solid pseudopapillary tumors of the pancreas. JOP: Journal of the Pancreas, 2014, 15, 561-8.	1.5	18
116	Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk. Molecular Carcinogenesis, 2013, 52, 103-109.	2.7	6
117	Up-front Hepatic Resection for Metastatic Colorectal Cancer Results in Favorable Long-term Survival. Annals of Surgical Oncology, 2013, 20, 295-304.	1.5	46
118	Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology, 2013, 58, 1693-1702.	7.3	264
119	Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer. Cancer Epidemiology, 2013, 37, 424-427.	1.9	24
120	Genetic Variants in Vitamin D Pathway Genes and Risk of Pancreas Cancer; Results from a Population-Based Case-Control Study in Ontario, Canada. PLoS ONE, 2013, 8, e66768.	2.5	40
121	Blood oxygen levelâ€dependent liver MRI: Can It predict microvascular invasion in HCC?. Journal of Magnetic Resonance Imaging, 2013, 37, 692-699.	3.4	20
122	Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice. Journal of Visualized Experiments, 2013, , e50544.	0.3	13
123	Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk. Carcinogenesis, 2012, 33, 818-827.	2.8	39
124	Clinical and Economic Comparison of Laparoscopic to Open Liver Resections Using a 2-to-1 Matched Pair Analysis: An Institutional Experience. Journal of the American College of Surgeons, 2012, 214, 184-195.	0.5	51
125	Liver resection for multifocal hepatocellular carcinoma Journal of Clinical Oncology, 2012, 30, 355-355.	1.6	2
126	Biliary tract cancer: A large institutional experience Journal of Clinical Oncology, 2012, 30, 4109-4109.	1.6	0

#	Article	IF	Citations
127	Outcome of adjuvant therapy for biliary tract cancers Journal of Clinical Oncology, 2012, 30, e14592-e14592.	1.6	0
128	Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion. Annals of Surgery, 2011, 253, 166-172.	4.2	245
129	Predictors of peri-opertative morbidity and liver dysfunction after hepatic resection in patients with chronic liver disease. Hpb, 2011, 13, 559-565.	0.3	44
130	Risks of cancers for carriers of monoallelic MUTYH mutation with a family history of colorectal cancer. Hereditary Cancer in Clinical Practice, 2011, 9, P40.	1.5	0
131	Cancer risks for monoallelic <i>MUTYH</i> mutation carriers with a family history of colorectal cancer. International Journal of Cancer, 2011, 129, 2256-2262.	5.1	93
132	Association of Hepatic Hemangiomatosis With Giant Cavernous Hemangioma in the Adult Population: Prevalence, Imaging Appearance, and Relevance. American Journal of Roentgenology, 2011, 196, 809-815.	2.2	29
133	Carcinoma of the Biliary Tract. , 2011, , 251-299.		1
134	Cigarette Smoking, Genetic Variants in Carcinogen-metabolizing Enzymes, and Colorectal Cancer Risk. American Journal of Epidemiology, 2010, 172, 1000-1014.	3.4	92
135	Germline MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study. Gastroenterology, 2009, 136, 1251-1260.	1.3	197
136	Missense Polymorphisms in the Adenomatous Polyposis Coli Gene and Colorectal Cancer Risk. Diseases of the Colon and Rectum, 2008, 51, 1467-1474.	1.3	12
137	Surgery for Gallbladder Cancer: A Population-Based Analysis. Journal of the American College of Surgeons, 2008, 207, 371-382.	0.5	109
138	Characterization of Mutant MUTYH Proteins Associated With Familial Colorectal Cancer. Gastroenterology, 2008, 135, 499-507.e1.	1.3	89
139	Treatment Considerations for Gallbladder Cancer Should Include Extent of Surgery. Journal of Clinical Oncology, 2008, 26, 4521-4522.	1.6	7
140	Neuroendocrine Tumors of the Gastrointestinal Tract. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 64-70.	1.3	50
141	Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients. Journal of Surgical Oncology, 2007, 95, 499-506.	1.7	31
142	Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery, 2007, 141, 330-339.	1.9	350
143	Cancer of the Gallbladder and Extrahepatic Bile Ducts. Current Problems in Surgery, 2007, 44, 396-482.	1.1	29
144	An Analysis of Resection vs Transplantation for Early Hepatocellular Carcinoma: Defining the Optimal Therapy at a Single Institution. Annals of Surgical Oncology, 2007, 14, 2608-2614.	1.5	88

SEAN P CLEARY

#	Article	IF	CITATIONS
145	Prognosis and Results After Resection of Very Large (≥10Âcm) Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2007, 11, 589-595.	1.7	80
146	Accuracy of Staging as a Predictor for Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation, 2006, 81, 1633-1639.	1.0	118
147	Risk of Colorectal Cancer in Monoallelic and Biallelic Carriers of MYH Mutations: A Population-Based Case-Family Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 312-314.	2.5	172
148	Association Between Biallelic and Monoallelic Germline MYH Gene Mutations and Colorectal Cancer Risk. Journal of the National Cancer Institute, 2004, 96, 1631-1634.	6.3	239
149	Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors1. Journal of the American College of Surgeons, 2004, 198, 722-731.	0.5	300
150	Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Research, 2003, 63, 1769-71.	0.9	45
151	Integration of Genomic and Transcriptomic Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. SSRN Electronic Journal, 0, , .	0.4	O